Skip to main content
Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: Use of constitutive and inducible oncogene-containing iPSCs as surrogates for transgenic mice to study breast oncogenesis

Fig. 1

Retroviral transfection of tail vein fibroblasts and selection of iPSC clones. Different transgenic, bitransgenic, tritransgenic, and background mice were used to isolate and prepare tail vein fibroblasts. All tail vein-derived fibroblasts appeared similarly (a). pMXs-mSox2, pMXs-mOct3/4, pMXs-mKlf4, pMXs-mc-Myc, and pMX-GFP were separately transfected into a Platinum-A retroviral packaging cell line to produce retroviruses. The retroviruses from the preceding step were equally mixed and transduced into fibroblasts. Colonies became visible approximately 8–15 days after the retroviral infection. Morphology of an emerging colony of the monolayer by phase contrast (b), its appearance on a feeder layer (c), and its GFP autofluorescence (d) are displayed. A emerging embryoid body from one of the iPSC clones is also depicted (e). Most emerging iPSC clones were positive for alkaline phosphatase, a known iPSC marker. Select iPSC clones exhibited typical markers of pluripotent stem cells, e.g., SSEA-1 (f) with control (g). The number of retroviral integration sites in representative clones ranged from an average of 1.0 to 2.0 / retroviral construct based on qPCR

Back to article page